Syngeneic  models

ONCOLOGY

Oncology is an area that commands a larger proportion of the research world's resources. Porsolt is now able to provide services using its Oncology in vitro capabilities and expertise through the acquisition of Fluofarma.

Syngeneic models

Syngeneic mouse models

With the rise of cancer immunotherapy, syngeneic mouse models have regained a big interest in drug discovery for oncology research. In these models, the mouse tumor allograft grows in close contact with an intact immune system. Immunologically-based therapies can therefore be tested, either alone or in combination, in order to find potentially new therapeutic strategies.

In this context, Porsolt has validated two syngeneic mouse models which allow for the testing of new immmuno-therapies as well as innovative targeted therapies.

Our immuno-sensitive model is based on the inoculation of the CT-26 colon cancer cells whereas our immunoresistant model relies on the injection of 4T1 breast cancer cells.

Optional studies in satellite mice

> Cytokine analysis in serum :
• ELISA
• CBA

> Immune response profiling (tumor, spleen etc…) :
• Immunochemistry
• Immunophenotyping by flow cytometry
    - T cells panel (Treg & TILS): CD45/CD4/CD25/CD8/FoxP3, in multiplex detection
    - Myeloid-monocytic cell panel (TAMS): CD45/CD11b/Gr1/CD11c, in multiplex detection. Other markers can be considered (e.g. NK1.1…)